PE20231185A1 - Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica - Google Patents

Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica

Info

Publication number
PE20231185A1
PE20231185A1 PE2023001369A PE2023001369A PE20231185A1 PE 20231185 A1 PE20231185 A1 PE 20231185A1 PE 2023001369 A PE2023001369 A PE 2023001369A PE 2023001369 A PE2023001369 A PE 2023001369A PE 20231185 A1 PE20231185 A1 PE 20231185A1
Authority
PE
Peru
Prior art keywords
cystic fibrosis
modulators
transmembrane conductance
regulator
compounds
Prior art date
Application number
PE2023001369A
Other languages
English (en)
Inventor
Bryan A Frieman
Jason Mccartney
Alexander Russell Abela
Sunny Abraham
Corey Don Anderson
Vijayalaksmi Arumugam
Jaclyn Chau
Jeremy Clemens
Thomas Cleveland
Timothy Richard Coon
Timothy A Dwight
Lev Tyler Dewey Fanning
Peter Grootenhuis
Anton V Gulevich
Ruah Sara Sabina Hadida
Yoshihiro Ishihara
Haripada Khatuya
Paul Krenitsky
Vito Melillo
Mark Thomas Miller
Prasuna Paraselli
Fabrice Pierre
Alina Silina
Joe A Tran
Johnny Uy
Lino Valdez
Jinglan Zhou
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of PE20231185A1 publication Critical patent/PE20231185A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDO A COMPUESTOS MACROLIDOS DE FORMULA (I) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN DONDE LOS ANILLOS A Y B, W1, W2, Z, L1, L2, R3, R4, R5 Y RYN SON TAL COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: (11R)-6-[2-(HIDROXIMETIL)-6-METIL-FENIL]-11-ISOBUTIL-2,2-DIOXO-12-ESPIRO[2.3]HEXAN-5-IL-9-OXA-2 LAMDA 6-TIA-3,5,12,19-TETRAZATRICICLO[12.3.1.14,8]NONADECA-1(18),4(19),5,7,14,16-HEXAEN-13-ONA; (11R)-6-(2,6-DIMETILFENIL)-11-ISOPENTIL-12-[1-(2-METOXIETIL)PIRAZOL-4-IL]-2,2-DIOXO-9-OXA-2 LAMDA 6-TIA-3,5,12,19-TETRAZATRICICLO[12.3.1.14,8]NONADECA-1(18),4(19),5,7,14,16-HEXAEN-13-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS. DICHOS COMPUESTOS SON MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUISTICA (CFTR) SIENDO UTILES EN EL TRATAMIENTO DE FIBROSIS QUISTICA.
PE2023001369A 2020-10-07 2021-10-06 Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica PE20231185A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063088935P 2020-10-07 2020-10-07
PCT/US2021/053860 WO2022076624A1 (en) 2020-10-07 2021-10-06 Modulators of cystic fibrosis transmembrane conductance regulator

Publications (1)

Publication Number Publication Date
PE20231185A1 true PE20231185A1 (es) 2023-08-11

Family

ID=78771139

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001369A PE20231185A1 (es) 2020-10-07 2021-10-06 Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica

Country Status (20)

Country Link
US (1) US20230382925A1 (es)
EP (1) EP4225764A1 (es)
JP (1) JP2023545081A (es)
KR (1) KR20230104618A (es)
CN (1) CN116783204A (es)
AR (1) AR123709A1 (es)
AU (1) AU2021358063A1 (es)
BR (1) BR112023006381A2 (es)
CA (1) CA3197857A1 (es)
CL (1) CL2023000984A1 (es)
CO (1) CO2023005734A2 (es)
CR (1) CR20230200A (es)
DO (1) DOP2023000066A (es)
EC (1) ECSP23032164A (es)
IL (1) IL301755A (es)
MX (1) MX2023004074A (es)
PE (1) PE20231185A1 (es)
TW (1) TW202233635A (es)
UY (1) UY39460A (es)
WO (1) WO2022076624A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150236A1 (en) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
WO2023150237A1 (en) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2023196429A1 (en) * 2022-04-06 2023-10-12 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2023224931A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2024056798A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators
WO2024056791A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
WO2024056779A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
MX341797B (es) 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US20110064811A1 (en) 2005-12-28 2011-03-17 Patricia Hurter Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
WO2007134279A2 (en) 2006-05-12 2007-11-22 Vertex Pharmaceuticals Incorporated Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
RS55360B1 (sr) 2007-12-07 2017-03-31 Vertex Pharma Proces za proizvodnju cikloalkilkarboksiamido-piridin benzoevih kiselina
CA2706920C (en) 2007-12-07 2018-02-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN102231990B (zh) 2008-08-13 2013-09-25 沃泰克斯药物股份有限公司 N-[2，4-双(1，1-二甲基乙基)-5-羟基苯基]-1，4-二氢-4-氧代喹啉-3-甲酰胺的药物组合物和其给药
EP2349223A2 (en) 2008-09-29 2011-08-03 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
SI2365972T1 (sl) 2008-11-06 2015-04-30 Vertex Pharmaceuticals Incorporated Modulatorji prenaĺ alcev z atp-vezavno kaseto
MX2011009867A (es) 2009-03-20 2012-01-12 Vertex Pharma Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quistica.
CA3016080C (en) 2010-03-25 2019-08-20 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
AU2011237368B2 (en) 2010-04-09 2015-07-23 Ekso Bionics Exoskeleton load handling system and method of use
JP2013525371A (ja) 2010-04-22 2013-06-20 バーテックス ファーマシューティカルズ インコーポレイテッド シクロアルキルカルボキサミド−インドール化合物の製造方法
NZ603042A (en) 2010-04-22 2015-02-27 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
CN103153286A (zh) 2010-08-27 2013-06-12 沃泰克斯药物股份有限公司 药物组合物及其施用
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
JP6063455B2 (ja) 2011-05-18 2017-01-18 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたイバカフトルの誘導体
CN109966264A (zh) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 药物组合物及其施用
CA2878057A1 (en) 2012-07-16 2014-01-23 Rossitza Gueorguieva Alargova Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
CA2890106C (en) 2012-11-02 2022-08-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
MY178621A (en) 2012-11-19 2020-10-19 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
DK3424534T3 (da) 2014-04-15 2021-07-26 Vertex Pharma Farmaceutiske sammensætninger til behandling af sygdomme medieret af cystisk fibrosetransmembranledningsregulator
EP4292588A3 (en) 2015-09-21 2024-02-28 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
WO2018080591A1 (en) 2016-10-27 2018-05-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated cftr potentiators
SG11202006614VA (en) * 2018-02-15 2020-08-28 Vertex Pharma Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
AR118555A1 (es) * 2019-04-03 2021-10-20 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
JP2022544383A (ja) * 2019-08-14 2022-10-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒモジュレータの結晶形態

Also Published As

Publication number Publication date
AU2021358063A1 (en) 2023-05-18
ECSP23032164A (es) 2023-06-30
DOP2023000066A (es) 2023-07-09
KR20230104618A (ko) 2023-07-10
US20230382925A1 (en) 2023-11-30
TW202233635A (zh) 2022-09-01
EP4225764A1 (en) 2023-08-16
UY39460A (es) 2022-05-31
MX2023004074A (es) 2023-07-05
CN116783204A (zh) 2023-09-19
CA3197857A1 (en) 2022-04-14
WO2022076624A1 (en) 2022-04-14
AR123709A1 (es) 2023-01-04
IL301755A (en) 2023-05-01
CO2023005734A2 (es) 2023-07-21
BR112023006381A2 (pt) 2023-09-26
CL2023000984A1 (es) 2023-11-24
JP2023545081A (ja) 2023-10-26
CR20230200A (es) 2023-07-13

Similar Documents

Publication Publication Date Title
PE20231185A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
MD3752510T2 (ro) Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora
CO2019008531A2 (es) Análogos de atazanavir (atv) para tratar infecciones por vih.
AR050838A1 (es) Formulacion farmaceutica. para el tratamiento de una infeccion optica
PE20200739A1 (es) Pirrolopirimidinas como potenciadores de cftr
PE20010130A1 (es) Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion
PE20230376A1 (es) Compuestos moduladores de la diacilglicerol quinasa
UY30310A1 (es) Derivados 2-azetidinona, sales, solvatos, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
CY1114908T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
AR048039A1 (es) Profarmacos de piperazina y agentes antivirales de piperidina sustituidos
PE20231951A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20231108A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
SE9904508D0 (sv) New compounds
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
MA40219A (fr) Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
PE20240050A1 (es) Inhibidores de cdk2 y metodos de uso de los mismos
BRPI0515344A (pt) composto, composição farmacêutica, e, usos de uma quantidade eficaz de um composto 3-fosfoindol ou sal, pró-droga, estereoisÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo e de uma quantidade de tratamento eficaz anti-hiv de um composto de 3-fosfoindol ou sal, pró-droga, estereo-isÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo
JP2018526391A5 (es)
UY28924A1 (es) Compuestos antibioticos particularmente conteniendo anillos de oxazolidinona y isoxazolina sustituidos, composiciones farmaceuticas, preparación, intermedios para ello y su uso terapeutico.
UY27577A1 (es) Inhibidores de la integrasa del vih